Drugs / S 81694
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03411161 | Jan 2018 → Jun 2020 | triple-negative breast carcinoma | Servier | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S 81694 | “S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D).” NCT03411161 ↗ |
| Route | Intravenous | “S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D).” NCT03411161 ↗ |